Radiation boost may tame brain spread in lung cancer
NCT ID NCT06741085
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. Researchers want to see if adding a precise, one-time radiation treatment (SRS) to the standard drug osimertinib is better than the drug alone at controlling brain tumors. About 56 participants will be followed for at least 3 months, and their quality of life will be tracked through questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib (a targeted oral drug) and stereotactic radiosurgery (SRS, a precise radiation treatment)
- What this could lead to
- If successful, this could show that adding focused radiation to standard drug therapy improves control of brain metastases and quality of life for people with EGFR-mutant lung cancer.
- What could go wrong
- This is a small, early-phase trial (56 participants) and may not prove that the combination is better. Radiation can cause side effects like brain swelling or fatigue, and the benefit may not be large enough to change standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BAPTIST ALLIANCE - MCI (Data Collection Only)
RECRUITINGMiami, Florida, 33143, United States
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITINGRockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict frailty in serious illness? a large study investigates
- Can a triple-drug cocktail re-sensitize lung cancer to treatment?
- Could a lung cancer drug designed for one mutation work for another?
- Could chemo plus immunotherapy double the punch against tough lung cancers?
- Engineered immune cells take aim at brain tumors
- Could targeted drugs spare brain cancer patients from radiation after surgery?